Medical cannabis lozenges and compositions thereof
View Patent ↗A method for optimizing the therapeutic effects provided by CBD on the one hand, and the psychoactive effects provided by THC on the other hand, in a sublingual medicament, the method includes the steps of obtaining a concentrated extract of cannabis in which the concentration of CBD is known and the concentration of THC is known, formulating a hydrophilic mixture containing ingredients such as sugar, corn syrup, xylitol, purified water, organic flavorings, coconut oil, and concentrated extract of cannabis , wherein the amount of CBD is as high as possible and where the amount of THC is precisely controlled, forming lozenges, and administering the medicament.
1. A lozenge for sublingual administration of a medicament consisting essentially of heat decarboxylated CO2-extracted cannabis sativa oil, heat decarboxylated CO2-extracted cannabis indica oil, xylitol and an ingredient selected from the group consisting of sugar, corn syrup, flavorings, coloring agents, coconut oil, purified water and mixtures thereof, the lozenge having a mass of between 2 grams and 15 grams, wherein the lozenge contains a minimum of 25 mg of cannabidiol and a maximum of 40 mg of tetrahydrocannabinol.
2. A method for minimizing the psychoactive effects of tetrahydrocannabinol in a therapeutic treatment of a human patient, the method consisting essentially of:
a) formulating a lozenge consisting essentially of heat decarboxylated CO2-extracted cannabis sativa oil, heat decarboxylated CO2-extracted cannabis indica oil, xylitol and an ingredient selected from the group consisting of sugar, corn syrup, flavorings, coloring agents, coconut oil, purified water and mixtures thereof, the lozenge having a mass of between 2 grams and 15 grams, wherein the lozenge contains a minimum of 25 mg of cannabidiol and a maximum of 40 mg of tetrahydrocannabinol; and
b) administering the lozenge of claim 1 sublingually to a human until the lozenge is dissolved in the human, thereby minimizing the psychoactive effects of tetrahydrocannabinol on the patient.
3. A method of preparing a lozenge for sublingual administration of a medicament containing cannabidiol and tetrahydrocannabinol to a human patient, the method comprising the following steps:
selecting a sativa cannabis in which the amount of cannabidiol and tetrahydrocannabinol is known;
selecting an indica cannabis in which the amount of cannabidiol and tetrahydrocannabinol is known;
heating the sativa cannabis and the indica cannabis to a temperature not higher than 190 degrees Fahrenheit for a period of time sufficient to cause decarboxylation of the cannabinoids contained therein;
extracting the sativa cannabis and the indica cannabis with CO2; and
formulating the lozenge with xylitol and an ingredient selected from the group consisting of sugar, corn syrup, flavorings, coloring agents, coconut oil, purified water and mixtures thereof, the lozenge having a mass of between 2 grams and 15 grams, whereby the lozenge contains a a minimum of 25 mg of cannabidiol and a maximum of 40 mg of tetrahydrocannabinol.